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Abstract 
Within every functional healthcare system, access to quality and affordable essential 
medicine stands out as one of the building blocks. However, its significance has been 
underrated due to poor advocacy and research. The implication is that access to quality 
and affordable essential medicines remains a challenge to many people in low / middle 
income countries and could create difficulty in the attempt to reform healthcare systems 
and save lives if not given ample attention. This paper presents a critical discussion of the 
Nigerian health system with special focus on access to essential medicines as a component 
of the Nigerian healthcare system by drawing upon primary data, using qualitative 
research method. 
 
Introduction 
Over the past 30 years, the issue of access to affordable essential medicine in a healthcare 
system has been a matter of worldwide concern1. In fact, since the 1976 Alma Ata, it has 
become part of the health system discourse2; literature survey revealed that the health of a 
country’s general population is significantly affected by the access to health care and 
availability/affordability of medicines3,4. Consequently, it is not surprising that policy 
makers, practitioners and other stakeholders in the health sector should be concerned 
about poor access to essential medicines.3 
 
However, little has been written on this issue, especially in Nigeria where the government 
and healthcare policy makers are trying to ensure greater access to medicines (ATM) 
through the introduction of programmes such as ‘the revolving drug fund’(Sambo et al, 
2008). It is worth mentioning that according to WHO 30% of the world’s population, 
(ranging between: 1.3 and 2.1 billion people), are estimated not to have regular access to 
essential medicines (EM).4. This paper discusses access to essential medicines in Nigeria 
with the simple aim of bringing the issue to wider attention. It is a product of a current 
study of access to essential medicines, which aims generally to contribute to filling the gap 
on the subject in Nigeria. The discussion in this paper includes a critical look at the notion 
of essential medicines and provides a contribution to the basis for the analysis of access to 
medicines within a health system. 
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Underlining Rationale and Conceptualisation of Essential Medicines 
The essence of making the essential medicines (EM) list flexible, according to the World 
Health Assembly,5 was to increase the collection and availability of medicines for areas 
with poor access6 and also, to ensure that countries create their own lists to suit their 
primary healthcare needs as affirmed by the 1978 Alma Ata declaration on primary 
healthcare. The declaration states, “the provision of essential medicine is a vital and 
dominant part of primary healthcare”. 7   In 1977, the WHO established an Expert 
Committee on EM to help member countries in the selection and procurement of 
medicines. The report of theexpert committee marked the ‘formal launch’ of the concept 
known as essential medicines (EM) given the fact that it established the criterion for 
medicines classification as well as the introduction of the first EM list abbreviated as 
‘WHO-EML’, which comprised approximately 200 medicines. The list was subject to 
revision every two years. . The Model List of EM is currently being used by countries as a 
guide for the development of their own national EML8 which serves as: the basis for 
procurement and supply of medicines in the public and private sector, development of 
schemes that reimburse medicine costs, medicine donations and to guide local medicine 
production9. 
 
The conceptualisation of EM was predicated on the fact that medicines are fundamental 
parts of the health care and the idea of present day health care systems are inconceivable 
without the availability of EM. Medicines do not only save lives and promote health, but 
prevent epidemics and diseases too. Therefore, the notion that medicines are undeniably 
one of the means for controlling diseases makes it the fundamental right of every human 
being. This further implies that accessibility to medicines is equally the fundamental right 
of every one. The issue of ‘rights’ in the field of health dates back to the WHO constitution 
of 1946, as part of social rights which details the progressive realization of the rights to 
health through four concrete steps, which includes access to health facilities, goods and 
services10. 
 
Furthermore, the 22nd session of the United Nations11 Committee on Economic, Social 
and Cultural Rights often referred to as ‘the general comment’ affirmed rather 
authoritatively, the principles of ATM as accessibility, availability, acceptability and 
assured quality to goods and services which includes not just EM but other medical 
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 diagnostics, supplies and consumables23- 12 . These pronouncements marked the 
confirmation that access to medicines was a global issue. However, the debate on ‘Access 
to Essential Medicines’ started in the late 1970s and 1980s when strong pressure from 
public health advocates led the pharmaceutical industry to accept the concept, which is 
now back on the international health policy agenda13. 
 
The clear identification of EM and the consequent provision of a list helped in firming up 
the notion of ATM due to concerns. These concerns were also intensified by the 
prevalence of very toxic or ineffective medicines and difficulty in treating patients due to 
the fact that the required medicines are too expensive or no longer manufactured14. 
 
Oliver and Mossialos15 are of the view that there is no universally accepted definition of 
the term ‘Access’. Peters et al. (2008)16 however, posited that ‘access’ might be considered 
as ‘the timely use of services according to needs’…, reflecting a general concept that sums 
up a set of more precise dimensions adjusting between the patient and the health care 
system (Penchansky and Thomas, 1981)17. 
 
ATM is influenced by several factors out of which the demand and supply side features 
prominently (Penchansky and Thomas, 1981; Ensor and Cooper, 2004)29. These 
dimensions 18  are; availability, accessibility, affordability and acceptability otherwise 
known as the 4As. The 4As was first suggested by Penchansky and Thomas in 1981 and 
years later adopted by WHO30. The application of the demand and supply dimension to 
the understanding of ATM incorporates the ability of individuals’, households’ and 
communities’ to use services vs aspects of health services and the health sector that 
hinder service utilization. 
 
Globally, medicines and diagnostic products are costly, non-existent, difficult to get or of 
low quality19. However, in Africa, more than 70% of the population are affected20 by EM 
issue which were available to 30% of all public and private health facilities in Africa21. 
Conceivably, the current state of global healthcare22 prompted WHO and African leaders 
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 under the platform of African Commission Resolution on the Right to Health and Access 
to needed Medicines in Africa23 into contextualising the 4As of ATM thus: 
 
Table 1 - : The Right of Health and Access to needed Medicines on Africa 
(WHO,2000). 
 
Availability The availability in sufficient quantities of needed (essential) 
medicines, including existing medicines and the 
development of new medicines needed for the highest 
attainable level of health 
Accessibility The accessibility of needed medicines to everyone without 
discrimination. It includes; Physical accessibility of needed 
medicines to all. 
Affordability Affordability or economic accessibility of needed medicines 
to all; Information accessibility about the availability and 
efficacy of medicines. 
Acceptability The Acceptability of medicine supplies, being respectful of 
cultural norms and medical ethics. 
Quality The quality of medicine supplies, ensuring that available 
medicines are safe, effective and medically appropriate. 
 
World Health Organisation: 2000 & Penchansky et al: 1981 
In the context of Africa therefore, Access to Medicine - ATM is based on the notion that it 
is the “percentage of population who have access to a minimum list of 20 essential 
medicines, which are continuously available and affordable at a health facility or 
medicines outlet, within one hour’s walk from the patient’s home”24. Besides, rational use 
and the quality of medicines are also in the definition of ATM, as contained in WHO 
policy document of 2007. This is in understanding and acknowledging the fact that the 
concept of access goes beyond the general understanding. This definition proposes that in 
order to guarantee full access to medicine, countries and health systems must ensure that 
their strategies include but not limited to what would be regarded as the four A’s25 of 
access: Availability, Affordability, Accessibility and Acceptability with its associated 
demand and supply aspects as proposed by Penchansky26. These four dimensions of ATM 
would allow a critical engagement with the access to essential medicines in Nigeria and an 
examination of its significance as a critical factor in the functioning of the Nigerian health 
system. 
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 Access to Medicines as part of a Health System 
Theoretical and empirical studies of access to health care have emphasized the 
importance of ATM27,40 and how this affects healthcare outcomes40. This was alluded to in 
the introduction. ATM and access to health care are closely intertwined given the fact that 
the commonest constraints in access to healthcare facilities, either public or private, affect 
ATM. Furthermore, availability of medicines has been cited in literatures28,29 as a key 
factor in access to healthcare as well as utilization30 of healthcare. When assessing a 
health system from a holistic perspective, the WHO and other stakeholders in healthcare 
have used availability of essential medicines as a measure of quality of care31. However, 
irrespective of the significant progress made by the WHO in advertising the EM list and 
publicising the concept of EM, the benefit has not been far reaching32, especially, in Africa 
and Asia. This raises the question of access to EM; what are the demand / supply 
constraints regarding ATMs? Can one say the global community is equipped to tackle the 
complexities surrounding ATM if countries do not understand the importance of ATM as 
a part of the health system? The issues being highlighted in this paper becomes also 
critical in terms of achieving goals four, five and six of the Millennium Development Goals 
(MDGs). This is because the number of preventable deaths; under five mortality rate, 
maternal mortality, and diseases; resistance to malaria etc. could be reduced if quality 
medicines are accessible, affordable and equitably distributed in time. In as much as it is 
generally argued that the high mortality rate in Africa could be reduced by access to 
quality medicines the term, access, has often been mistaken for entry and or use of a 
healthcare facility/ services. Whereas, Access to Medicine as a concept, as earlier 
discussed, comprises distinct dimensions33, which are influenced by an array of specific 
relationships among availability, accessibility, quality, affordability and acceptability 
(Penchansky34 and O’Donnel35). 
 
Access as Availability 
As a dimension of access to medicines, availability is defined by the relationship between 
the type and quantity of product or service needed, and the type and quantity of product 
or service provided36. It is highly dependent in the location of the service provider and 
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 also the location of the household. This dimension of access takes into account, the WHO 
and UNDP’s definitions37  of having medicines constantly available and affordable at 
public or private health facilities or medicine outlets that are within one hour’s walk from 
the home of the population. For example, Goddard & Smith38, described availability as 
increasing the number of facilities, in order to reduce the time it takes to reach the closest 
facility, an important first step. However, greater provision of facilities that can deliver 
effective care is necessary but is not, in itself sufficient. Availability of a healthcare facility 
does not necessarily guarantee care as proven by Florence Nightingale 39  during the 
Crimean War, where she discovered that access to a hospital actually increased the chance 
of dying, primarily because of the failure to address the risk of infection since the required 
medicine was not obtainable. Availability of medicines is a supply side dimension of ATM 
because it indicates the level of service which the health system offers the individual. 
 
Penchanky’s taxonomy40 distinguished availability as the relationship of the volume and 
type of existing services (and resources) to the clients’ volume and types of needs. It refers 
to the adequacy of the supply of physicians, dentists and other providers; of facilities such 
as clinics and hospitals; and of specialised programs and services such as mental health 
and emergency care. This suggests that if a patient suffers certain ailment, and in the case 
of any emergency, he or she should be able to obtain the right treatment at first call. The 
demand and supply aspect to this dimension of access simply means that bio medical 
healthcare workers, medicines and diagnostics would be the supply side while the 
demand for the services would remain the demand side. 
 
Access as Acceptability 
Within ATM, acceptability as defined by Penchansky and Thomas41 is “the relationship of 
clients’ attitudes about personal and practice characteristics of providers to the actual 
characteristics of existing providers, as well as to provider attitudes about acceptable 
personal characteristics of clients”42. In his work, the term appears to be used most often 
in reference to specific consumer reaction to provider qualities such as age, sex, ethnicity, 
type of facility, neighbourhood of facility, or religious affiliation of facility or provider. 
However, other authors also refer to it as consumer disposition to medicines with respect 
to safety, efficacy and side effects43. 
 
Similarly, providers have attitudes about the preferred attributes of clients or their 
financing mechanisms. Providers might either be unwilling to serve certain types of 
clients (e.g. poor people who rely on charity) or, through accommodation, may make 
themselves more or less available. Therefore, acceptability as a dimension of access to 
medicine is distinguished on grounds that the efficacy of a particular medicine has been 
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 proven, it is considered safe for use by all and consumers are satisfied which further 
compels utilization44. 
 
Access as Accessibility 
Here, accessibility is determined by the relationship between the location of the medicine 
and the location of the eventual user. While physical accessibility to medicines matter, 
there is also social accessibility, which is often ignored but plays a major role. Social 
accessibility comprises class structure, income, age, education, gender or ethnicity. The 
relationship between the location of supply and the location of users (demand), takes 
account of client transportation resources and travel time, distance and cost. Therefore, 
while the location of the service is considered the supply side, the household location 
becomes the demand side45. Again, if one has to look at accessibility from the demand and 
supply angle, the characteristics of the health services would represent the supply side 
while the attitude and expectations of patients would speak to the demand side46. 
 
Access as Affordability 
Affordability of medicine is the relationship between prices of the medicine or diagnostics 
and the user’s ability to pay for them. It is relationship of prices of services and providers’ 
insurance or deposit requirements to the clients’ income, ability to pay and existing health 
insurance. The clients’ perception of worth relative to total cost is a concern here, as is 
their knowledge of prices, total cost and possible credit arrangements47. Costs and prices 
of services fall under the supply side while household resources and willingness to pay 
falls under the demand side of affordability. 
 
While the outlined conceptual understanding of access is quite useful given the occasional 
misunderstanding, it is even more useful when barriers to access are part of the 
conceptualisation. As noted in the literature, there is no ultimate definition of barriers to 
access; nevertheless, the following is somehow widely accepted. 
 
Barriers to Access 
Peter et al.64 stating that ‘the timely use of services according to need”; and the other 
given by Penchansky and Thomas (1981)65 ‘as a fit between the clients and the health 
system clearly captures the different dimensions of what constitutes access to medicines 
as outlined in the WHO report.  These definitions of access indicate that there is a 
demand and supply side to ATM. Therefore, when we talk about barriers to ATM, it also 
raises the issue of the different sides of ATM. Ensor & Cooper48 suggested that the 
demand side barriers to access at the individual, household and community levels are 
influenced by factors such as; ‘Perceived quality of medicines and health services, Cost of 
medicines and services, Irrational health-seeking behaviour: Management staff efficiency, 
technology, household expectations, community and cultural preferences, attitudes and 
norms; demand for and use of medicines; waiting time, wages and quality of staff, price 
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 and quality of drugs and other consumables, information, education; Social and cultural 
barriers - stigma related to poverty, ethnicity and gender’49. All these factors contribute to 
reduced access to medicines. 
 
The supply side constraints to ATM focuses on the healthcare service provider/ facilities; 
According to Cameron et al., (2009)50, the supply side barrier to access has to do with 
service location, quality of the medicine: counterfeits / sub standards, affordability and 
availability51. Other scholars52 also cited unqualified health workers, staff absenteeism, 
opening hours, Information on health care services/providers, waiting time, Education/ 
Motivation of staff, irrational prescription and dispensing53. Essential medicines play a 
major role in healthcare delivery given the fact that the interaction between medicines 
and services yield positive health outcomes. However, there are numerous other 
multifaceted constraints to ATM which led to the underperformance of a lot of healthcare 
systems, especially in Low-income countries. How do we therefore understand access to 
essential medicines in light of the conceptual discussion so far? 
 
Access and Barriers to Essential Medicines in Nigeria 
ATM might not have been extensively researched in Nigeria as earlier noted, it is, 
however, an issue that draws the attention of policy makers and health professionals in 
the country. The significance attached to it is evident in various laws and organizations 
that have been established over the years in Nigeria to eliminate or reduce the barriers to 
it.54 As part of its efforts and commitment towards the equitable and timely distribution 
of quality and essential medicines, Nigeria adopted the enlisting procedure ‘WHO EML’17 
of EM and set up legislation to back it up in 198955. Yet, decades later, over 60%56 of its 
population still lack access to medicines. The primary goal of the Nigerian Medicines 
Policy is to ensure the availability of effective, quality and affordable medicine to all 
Nigerians at all times and in all sectors of the health care system. Yet, the population of 
people with access to essential medicines required for the treatment of acute and chronic 
sicknesses such as malaria and HIV is estimated at 40%57. While, from 2002 to 2012, the 
median availability of selected generic medicines in public facilities was 26.2% while that 
of the private sector was 36.4%58. 
 
The policy cuts across the four dimensions of ATM and each of the 4As have two 
constituents relating to demand and supply. On the other hand, the constraints to ATM in 
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 the country could be summed up as a lack of affordable healthcare coverage or long 
waiting times before innovative medicines are approved or made broadly available. The 
Nigerian government and other stakeholders in the health sector have made attempts at 
tackling the constraints of ATM in the country. Nevertheless, ATM in Nigeria still remains 
a big challenge. Statistics from Demographic and health Survey59 of the country between 
2004 and 201160 indicated poor medicine availability, particularly in the public sector. 
The WHO report stated that although basic medicines were generally more available in all 
outlets, a range of 34 priority medicines was particularly low within the public and private 
health facilities in Nigeria61. The survey also revealed that patients in Nigeria pay more 
than international reference prices for medicines in public and private facilities. 
 
In addition, although medicine costs in the public facilities were almost same with those 
in the private facilities, private health clinics were shown to charge up to 184% more than 
the public health facilities and 193% more than private retail pharmacies 62 . WHO 
statistics have shown that medicines are too expensive to 90.2% Nigerians who live below 
2 US dollars a day and these also included government employees who earn a minimum 
wage of 1.4 US dollars daily63. Affordability in Nigeria, as indicated in the survey report, 
was essentially dependent on the choice of therapeutic class, product or sector from which 
the medicine was bought. This further confirms the estimation that the percentage of Out-
of-Pocket expenditure as a proportion of private expenditure on health is about 94.5% in 
Nigeria64. 
 
Another baseline survey65 of the Nigerian Pharmaceutical Sector, showed that due to 
unavailability of key medicines in public health facilities (Only about 46% of a basket of 
key medicines were found in all facilities both public and private), patients in Nigeria 
utilize private healthcare facilities (private clinics, retail pharmacies, chemists, and 
mobile medicine sellers) resulting in over 95%66 of the populace using inappropriately 
prescribed drugs. Given the condition they find themselves, it would not be out of place to 
say that medicine sellers, local chemist shops (often untrained and unlicensed) and 
private pharmacies /clinics provide healthcare more than public facilities. 
 
ATM in Nigeria has been constrained by healthcare expenditure, which has been regarded 
as abysmally low when compared to the WHO standard. The Total expenditure on health 
as a percentage of gross domestic products in 2010 was 5.42% while general government 
expenditure on health as a percentage of total expenditure on health in 2011 was 36.6967. 
The total expenditure on health care as percentage of GDP is 4.6, while the percentage of 
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 federal government expenditure on health care is about 1.5%68. Although the Nigerian 
government spends about 70% of its healthcare budget69 in urban areas where 30% of the 
population live, there is no record of how much of this allocation goes into the 
procurement of medicines within these areas. 
 
A Business Day publication reported that: “The 2013 budget allocation to the healthcare 
sector is 239 billion and on a per capita basis, comes to N1, 680 as against a WHO 
recommendation that governments spend a minimum of N6, 908 per head, on providing 
healthcare services to their citizens”. The report added that the 2013 budgetary allocation 
to healthcare delivery is made even worse by the fact that 77 per cent or N77 of every 
N100 allocated to the Ministry, would be spent on paying personnel employed in the 
sector, leaving just N20 of every N100 spent, for capital expenditure incurred by over 50 
Federal Medical Centres and Teaching hospitals across the federation and just N3 of every 
N100 budgeted for healthcare to cover overheads incurred. The gap of N5, 224 per head 
at the Federal government level is too wide to be filled by autonomous spending from 
state government allocation. A closer look at the 2013 budget shows that out of the total 
budget, a low sum of 32,258,446 (thirty two million, two hundred and fifty eight 
thousand, four hundred and forty six naira) was allocated to drugs & medical supplies. 
 
The availability of EM in all sectors within Nigeria is also low especially, at 22.6% with 
half of the generic medicines found in 5.4% to 45.2% of the private pharmacies70. The 
average availability of all medicines in the three dominant sectors in Nigeria is 
represented in Table 2 below: 
 
Table-2: The availability of EM in different health sectors of Nigeria. 
Public facilities Private 
clinics 
Private Pharmacies 
Innovator brands – 2.4% 21.6% 5.1% 
Lowest Priced Generic medicines – 
2.6% 
34.1 % 16.7% 
Most Sold Generic medicines- 2.4% 13.6% 2.6% 
 
Source: Baseline Assessment of the prices people pay for medicines in 
Nigeria, 2006, published by the Federal Ministry of Health in collaboration 
with the World Health Organization. 
From the Table above, it is evident that the public and private health clinics stocked 
almost entirely lowest priced generic equivalent products while the private pharmacies 
had a mix of all products. Also, the availability of all medicines was lowest in private 
health clinics. The table also showed that availability of both innovator brand and generic 
medicines are mostly in private pharmacies. 
 
Approximately half of the generic medicines are found in both public and private health 
facilities and about a quarter of the innovator brands are found within the same facilities. 
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 For example, in terms of affordability, the survey71 specified that the most sold generic 
medicine was obtained at the lowest price in public health facilities but cost as much as 
143 times in private clinics. Also, the lowest price for a generic medicine known as 
Meprasil was found in private pharmacies but cost about 840% higher in private clinics. 
 
The minimum and maximum prices for the same medicine were more expensive in public 
facilities than in private pharmacies. This implies that all medicine prices are higher in 
private clinics but there is no pattern in the pricing of the same medicines in public 
facilities and private pharmacies. While some medicines are higher in public facilities, 
others are higher in private pharmacies. Generally, the prices of the same medicines are 
not so different in public facilities and private pharmacies, but show a large difference 
when compared with the cost in private clinics. 
 
A further look at the components of medicine prices in Nigeria shows that the import cost 
of most medicines is less than half of what the patient eventually pays. The rest is spread 
out over government tariffs and cost of distribution. Thus, it is evident that government 
levies, charges and supply costs make up a large part of the amount people pay for 
medicines as portrayed by a study of medicine pricing structure in Nigeria72. If that be the 
case, would a new pricing policy improve ATM and eliminate all pricing variations across 
all sectors? Presently, there is no standard medicine pricing policy in Nigeria- this 
perhaps explains pricing disparities in similar facility types within a particular 
geographical location. And, most importantly, it could probably account for high mark-
ups by importers and other pharmaceutical supply chain stakeholders. Nigeria’s 1989 
legislation on essential medicine contained protocols on how to control the production 
and importation of counterfeit / sub-standard drugs as well as harmful advertisements of 
health products73. However, despite the effort of the government, drug counterfeiting has 
remained an obstacle that has prevented people from having access to quality medicines. 
 
The high cost of medicines in private pharmacies and healthcare facilities coupled with 
scarcity of essential medicines in public facilities compels consumers to use 
inappropriately prescribed medicines. And, often times, these inappropriately prescribed 
(inappropriately prescribed medicines are those prescribed without due adherence to 
clinical guidelines such as proper diagnosis by a certified personnel) medicines are bought 
across the counter from unauthorised but cheap and easily accessible sources. 
Furthermore, counterfeits and substandard medicines are often supplied through various 
distribution networks such as public/private healthcare facilities (out of greed and other 
unspecified factors which could possibly be due to irregular supplies by the government; 
most bio medical healthcare personnel purchase medicines from the open market and sell 
to patients), private pharmacies, local unauthorised drug stores, and the Internet. And, 
they often have instant effect on patients who do not receive the necessary treatment as 
well as increasing their resistance to treatment for severe ailments. What does this mean 
for ATM? What is being suggested here is very simple: that medicines are available but 
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 what seems to be a problem is the access to medicines that are listed as essential 
generally, and adopted in Nigeria as such. The quality of these medicines, one would like 
to assume, is one of the reasons why there is still the resort to the use of traditional 
medicines in the country. In fact, the resort to and use of traditional medicines is 
prevalent in LICs. For example, data from the WHO shows that 80% of Asians and 
Africans depend on traditional medicine for primary health care due to their inability to 
access or afford essential medicines74 Statistics show that in many developed countries, 
70% to 80% of the population has used some form of alternative or complementary 
medicine (e.g. acupuncture)75. According to the WHO Traditional medicine has been 
defined as ” the sum total of knowledge, skills and practices based on the theories, beliefs 
and experiences indigenous to different cultures that are used to maintain health, as well 
as to prevent, diagnose, improve or treat physical and mental illnesses”76. 
 
Studies conducted in 2004 and 2010 show that traditional medicine remains the most 
affordable and accessible form of healthcare for most Africans, especially, the rural 
dwellers77. Having recognised and acknowledged the role of traditional medicine within 
the continent, the African Union declared 2001 to 2010 ‘the Decade for African 
Traditional Medicine’ with the aim of producing “safe, effective, quality, and affordable 
traditional medicines accessible to all78. Traditional medicine was considered primitive 
and backward in the past; however, its undeniable role in the delivery of healthcare and 
the threat of counterfeit which is associated with its relevance has compelled more than 
100 countries79 into setting up regulations for traditional/ herbal medicines. 
 
The importance of traditional medicines cannot be overemphasised given the fact that 
beyond its easy reach and affordability, it has been reputed to treat different kinds of 
infectious and chronic conditions 80 . Moreover, the WHO discovered that the new 
antimalarial drugs were developed from the discovery and isolation of artemisinin from 
Artemisia annua L., a plant used in China for almost 2000 years81. 
 
Although the general utilization ratio of traditional medicine in Nigeria is not totally 
documented, research has shown that there is a strong evidence of use by pregnant 
women107-09[82,83& 84], hypertensive85and asthmatic people86, children87, and cancer 
patients88. 
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 The use of traditional medicine is not new in Nigeria. Traditional / herbal Medicine has 
been the first choice of treatment for illnesses in Nigeria before the advent of western 
medicine. Most people who used traditional medicines in Nigeria always alluded to; the 
fact that it is organic and safe, easy to access, cheap as compared to the high cost of 
conventional healthcare and medicines, effective when used for prolonged illnesses that 
had defied conventional medicines89. Other motivating factors have been religious or 
cultural beliefs as well as the fact that traditional medicines do not come in strict doses90. 
 
Conclusion 
In conclusion, the issues surrounding ATM in Nigeria range from an uncoordinated 
medicines supply chain to lack of price regulation resulting in shortage of essential 
medicines in primary healthcare facilities across the country. These issues are all 
indicative of poor health system governance and weak coordination between health 
system leadership and operations. Therefore, there is need for the government to 
introduce strict and uniform medicines pricing mechanisms not just in the public sector 
(as evident in the NHIS medicines pricing list) but in private facilities as well to ensure 
that all citizens irrespective of their locations or income have timely access to essential 
medicines at all times. 
 
The issues and challenges that characterise access to essential medicines in the country 
are multi-dimensional; On the supply side, constraints such as poor coordination of 
medicines procurement and supply to public facilities leading to stock outs and shortage 
of medicines; a poorly regulated and laisses-faire market where wholesalers and 
distributors add high mark ups without due consideration or regard for the purchasing 
power of poor consumers results in high cost of medicines in the private sector: poor 
medicines financing by the government, the effects of which are visible in delayed 
treatments /poor access to most innovative and lifesaving medication in public facilities; 
low performance benchmark for professionals as a result of the weak monitoring system-
evident in absence of qualified personnel in both public and private facilities; neglect of 
village dispensaries by local and state governments, lack of synergy and information gap 
between the three tiers of government and other stakeholders. These are remote issues, 
but are summed up in the highlighted ones discussed in this paper. 
 
On the demand side: low education, low purchasing power, irrational use of medicines 
appear to be a direct factor of poor prescribing and dispensing practice. Even though 
there are policies and standard practice guidelines in place as evident in the national EM 
list, the challenge appears to be that of implementation, regulation, monitoring, synergy 
among stakeholders and sustainability of initiatives/projects. 
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